Immunic, Inc. (IMUX)

NCM – Real vaqt narxi. Valyuta: USD

11.90

-0.10 (-0.83%)

Yopilishda: May 12, 2026, 4:00 PM EDT

11.80

-0.10 (-0.87%)

Bozor oldidan: May 13, 2026, 8:54 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Immunic, Inc. (IMUX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Immunic, Inc. (IMUX)

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic: Saved By A 200 Million Private Placement

Immunic to Participate in Investor and Medical Conferences in May

Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic to implement 1-for-10 reverse stock split

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Videolar

No Data

Press-relizlar

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic to Participate in Investor and Medical Conferences in May

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Search stocks

Immunic, Inc. (IMUX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Immunic, Inc. (IMUX)

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic: Saved By A 200 Million Private Placement

Immunic to Participate in Investor and Medical Conferences in May

Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic to implement 1-for-10 reverse stock split

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Videolar

No Data

Press-relizlar

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic to Participate in Investor and Medical Conferences in May

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic, Inc. Announces 1-for-10 Reverse Stock Split